Advanced in Herpes Simplex Encephalitis

Dr. William J. Muller

Pediatric Infectious Disease | Infectious Disease
225 E Chicago Ave, Box 20, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Herpes Simplex Encephalitis
225 E Chicago Ave, Box 20, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

William Muller is a Pediatric Infectious Disease specialist and an Infectious Disease provider in Chicago, Illinois. Dr. Muller is rated as an Advanced provider by MediFind in the treatment of Herpes Simplex Encephalitis. His top areas of expertise are Neonatal Herpes, Severe Acute Respiratory Syndrome (SARS), Herpes Simplex Encephalitis, and COVID-19.

His clinical research consists of co-authoring 261 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Herpes Simplex Encephalitis.

Specialties
Pediatric Infectious Disease
Infectious Disease
Licenses
Pediatric Infectious Diseases in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

225 E Chicago Ave, Box 20, Chicago, IL 60611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Enrollment Status: Recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections
An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections
Enrollment Status: Active_not_recruiting
Publish Date: July 25, 2025
Intervention Type: Drug
Study Phase: Phase 1
Assessment of CMV-specific T Cell Responses by Flow Cytometry With Intracellular Cytokine Staining to Predict CMV Infection Risk in Pediatric Solid Organ Transplant Recipients
Assessment of CMV-specific T Cell Responses by Flow Cytometry With Intracellular Cytokine Staining to Predict CMV Infection Risk in Pediatric Solid Organ Transplant Recipients
Enrollment Status: Active_not_recruiting
Publish Date: October 26, 2024
Intervention Type: Other
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Enrollment Status: Completed
Publish Date: September 06, 2023
Intervention Type: Drug
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Enrollment Status: No_longer_available
Publish Date: March 14, 2022
Intervention Type: Drug
View 6 Less Clinical Trials

261 Total Publications

Correction: Miniaturized scalable arrayed CRISPR screening in primary cells enables discovery at the single donor resolution.
Correction: Miniaturized scalable arrayed CRISPR screening in primary cells enables discovery at the single donor resolution.
Journal: Scientific reports
Published: September 30, 2025
Similar Doctors
Distinguished in Herpes Simplex Encephalitis
Dr. Lisa N. Akhtar
Pediatric Infectious Disease | Pediatrics
Distinguished in Herpes Simplex Encephalitis
Dr. Lisa N. Akhtar
Pediatric Infectious Disease | Pediatrics
225 E Chicago Ave, 
Chicago, IL 
 (0.1 miles away)
800-543-7362
Languages Spoken:
English
See accepted insurances

Lisa Akhtar is a Pediatric Infectious Disease specialist and a Pediatrics provider in Chicago, Illinois. Dr. Akhtar is rated as an Advanced provider by MediFind in the treatment of Herpes Simplex Encephalitis. Her top areas of expertise are Neonatal Herpes, Herpes Simplex Encephalitis, Kawasaki Disease, and Streptococcal Group A Infection.

Michael J. Anderson
Advanced in Herpes Simplex Encephalitis
Dr. Michael J. Anderson
Infectious Disease
Advanced in Herpes Simplex Encephalitis
Dr. Michael J. Anderson
Infectious Disease

Metro Infectious Disease Consultants, LLC

13755 Cicero Ave, 
Crestwood, IL 
 (18.5 miles away)
888-220-6432
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Anderson is an Infectious Disease provider in Crestwood, Illinois. Dr. Anderson is rated as a Distinguished provider by MediFind in the treatment of Herpes Simplex Encephalitis. His top areas of expertise are Osteomyelitis, Pneumonia, Lymphangitis, and Blastomycosis.

Advanced in Herpes Simplex Encephalitis
Dr. Ines M. Casey
Infectious Disease
Advanced in Herpes Simplex Encephalitis
Dr. Ines M. Casey
Infectious Disease

Metro Infectious Disease Consultants, LLC

1012 95th St, 
Naperville, IL 
 (31.0 miles away)
888-220-6432
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ines Casey is an Infectious Disease provider in Naperville, Illinois. Dr. Casey is rated as a Distinguished provider by MediFind in the treatment of Herpes Simplex Encephalitis. Her top areas of expertise are Sepsis, COVID-19, Osteomyelitis, and Lymphangitis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Muller's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile